CN100367956C - Medicine for treating hypertension - Google Patents

Medicine for treating hypertension Download PDF

Info

Publication number
CN100367956C
CN100367956C CNB2006101120684A CN200610112068A CN100367956C CN 100367956 C CN100367956 C CN 100367956C CN B2006101120684 A CNB2006101120684 A CN B2006101120684A CN 200610112068 A CN200610112068 A CN 200610112068A CN 100367956 C CN100367956 C CN 100367956C
Authority
CN
China
Prior art keywords
compositions
medicine
chinese medicine
alacepril
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006101120684A
Other languages
Chinese (zh)
Other versions
CN1911428A (en
Inventor
陈俊云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2006101120684A priority Critical patent/CN100367956C/en
Publication of CN1911428A publication Critical patent/CN1911428A/en
Application granted granted Critical
Publication of CN100367956C publication Critical patent/CN100367956C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

A synergistic medicine contains alacepril and the extracts of Chinese-medicinals and its application in preparing the medicines for treating hypertension are disclosed.

Description

Be used for the treatment of hypertensive medicine
Technical field
The invention belongs to a kind of medicine, a kind ofly specifically be used for the treatment of the hypertensive compositions that contains alacepril.
Background technology
Hypertension is common clinical, frequently-occurring disease.A large amount of research is verified, and hypertension is the most important risk factor of cardiovascular and cerebrovascular disease.The whole nation is three hypertension census results show, nineteen fifty-nine the hypertension prevalence of being grown up more than 15 years old be 7.73% for 5.11%:1979; Rose to 11.8% in 1991, and be ascendant trend year by year.At present, there are hyperpietic 9,000 ten thousand people in the whole nation, increase 3,000,000 hypertensive patients every year newly, corresponding therewith, annual apoplexy new cases 1,500,000, about 1,000,000 people of person that die from the apoplexy every year, the existing about 500-600 ten thousand of apoplexy number of patients, wherein about 75% has lost work capacity to some extent, and severe disabled person accounts for more than 40%, annual economic loss and the medical expense that causes thus is quite surprising, brought serious social concern and heavy financial burden to country.So doing a good job of it with prevention, control hypertension is the cardiovascular and cerebrovascular disease preventing and controlling of breach, has been the task of top priority.
At present, though doctor trained in Western medicine has obtained certain progress to hypertensive research, new medicine comes out, and brings new hope to controlling blood pressure, and the most toxic side effect of hypotensor is often taken for a long time and brought many iatrogenic diseases to the patient, loses more than gain.The period in a medicine blood pressure drops, blood pressure easily bounces after the drug withdrawal, and effect is difficult to lasting.Though blood pressure descends sometimes, clinical symptoms is not removed, and what have increases the weight of on the contrary, and the labour force can not recover.And new depressor costs an arm and a leg mostly, and general patient is difficult to bear, and is not inconsistent inconvenient penetration and promotion with China's national situation.In the face of new problem, Chinese medicine has been cooked a large amount of work in recent years preventing and treating aspect the hypertension, obtained gratifying achievement, demonstrated certain advantage, but clinical practice is based on traditional decoction, though curative effect is preferably arranged, so time-consuming because of decocting, the waste medical material, the dosage form transmutability is big, be difficult to problems such as large tracts of land popularization, make the patient be difficult to adhere to for a long time, thereby influenced the normal performance of curative effect, do not reach the intended purposes of control.Filtered out a collection of single medicinal material, though take easy, but because of kind, limited amount, simultaneously, also simple because of the single practical application, can not embody the tcm characteristic that dialectical opinion is controlled, exist the limitation identical too with Western medicine, though be that blood pressure had decline after many patients took medicine, clinical symptoms does not subtract, the irreclaimable problem of labour force.
No matter the Chinese medicine hypertension is controlled in dialectical opinion, and single medicinal material is used and the zoopery aspect proves that all hypotensive effect is definite, and has and have no side effect, and curative effect is lasting, is difficult for advantages such as recurrence.But, be difficult to grasp unfavorable promoting the use because dialectical pattern of syndrome is unfixing.Some single medicine of hiding is effective in cure, but is difficult to solve simultaneous phenomenon, and the single drug effect a little less than, escalated dose problem such as easily have side effects again.
The present invention attempts Chinese medicine and Western medicine are combined, and with the problem of avoiding existing separately, and improves hypertensive therapeutic effect, promptly produces synergism.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of alacepril and a kind of Chinese medicine extract, wherein prepares on the basis of the Chinese medicine extract of said composition according to the 6th page of specific embodiment of Chinese patent CN1150930C description, and is as follows:
Take by weighing 1 part of Ramulus Cinnamomi, 1 part of Radix Paeoniae Rubra, 1 part in Fructus Jujubae, 1 part in Rhizoma Zingiberis Recens, 0.7 part of Radix Glycyrrhizae Preparata, add 9 times distilled water, after water logging half an hour, heating extraction 2 times is boiled 30 minutes after-filtration at every turn, and residue discards, filtrate was reclaimed, and adds 70% ethanol precipitation, through 20 hours precipitations, decompress filter, discard residue, get and be dissolved in the ethanol part, reclaim ethanol, with 4 times of n-butanol extractions 7 times, each 2.5 hours n-butyl alcohol extractum.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the hypertensive medicine of preparation treatment.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong antihypertensive function, i.e. hypotensive activity.
The following medicine of respectively organizing is awarded spontaneous hypertensive rat (SHR) and mouthful raised administration 15 days, and the result all can obviously reduce the blood pressure of SHR.Experimental result sees the following form.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 0.98g/kg body weight as indicated above
3 alacepril groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight alacepril+extractum 0.98g/kg body weight mentioned above is irritated stomach.
Group (n=10) Blood pressure mmHg
0 day 5 days 15 days
Group 1 ?143.1±4.3 ?161.9±3.9 ?177.8±6.7
Group 2 ?140.7±4.8 ?135.6±3.9 ?131.9±4.8
Group 3 ?149.4±2.1 ?127.4±2.9 ?129.7±3.7
Group 4 ?151.9±3.9 ?120.2±3.7 ?116.7±4.1
This table shows that all there is significant difference (P<0.05) in each group (pure Chinese drug-treated group, alacepril group, compositions group) of treatment with model control group, and all there are significant difference (P<0.05) in compositions group and pure Chinese drug-treated group, compositions group and alacepril group.Show that there are cooperative effect in alacepril and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio alacepril and described Chinese medicine extract at 1: 98.
Can produce the capsule that contains following component in a conventional manner:
Component The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Pulvis Talci 5.0
Wherein compositions is made up of with weight ratio alacepril and described Chinese medicine extract at 1: 98.

Claims (2)

1. treat hypertensive compositions for one kind, it was made up of alacepril and Chinese medicine extract in 1: 98 by weight, wherein Chinese medicine extract is obtained by following method: take by weighing by weight 1 part of Ramulus Cinnamomi, 1 part of Radix Paeoniae Rubra, 1 part in Fructus Jujubae, 1 part in Rhizoma Zingiberis Recens, 0.7 part of Radix Glycyrrhizae Preparata, the distilled water that adds 9 times, after water logging half an hour, heating extraction 2 times is boiled 30 minutes after-filtration at every turn, residue discards, filtrate was reclaimed, and adds 70% ethanol precipitation, through 20 hours precipitations, decompress filter, discard residue, get and be dissolved in the ethanol part, reclaim ethanol, with 4 times of n-butanol extractions 7 times, each 2.5 hours n-butyl alcohol extractum.
2. the purposes of compositions as claimed in claim 1 in the hypertensive medicine of preparation treatment.
CNB2006101120684A 2006-08-29 2006-08-29 Medicine for treating hypertension Expired - Fee Related CN100367956C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2006101120684A CN100367956C (en) 2006-08-29 2006-08-29 Medicine for treating hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2006101120684A CN100367956C (en) 2006-08-29 2006-08-29 Medicine for treating hypertension

Publications (2)

Publication Number Publication Date
CN1911428A CN1911428A (en) 2007-02-14
CN100367956C true CN100367956C (en) 2008-02-13

Family

ID=37720592

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2006101120684A Expired - Fee Related CN100367956C (en) 2006-08-29 2006-08-29 Medicine for treating hypertension

Country Status (1)

Country Link
CN (1) CN100367956C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103143020B (en) * 2013-03-18 2014-06-11 李伟丽 Pharmaceutical composition for treating hypertensive left ventricular hypertrophy and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133304A (en) * 1997-12-23 2000-10-17 Warner-Lambert Company ACE inhibitor-MMP inhibitor combinations
CN1330556A (en) * 1998-11-06 2002-01-09 G·D·西尔公司 Combination therepy of angiotensin-converting enzyme inhibor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
CN1366986A (en) * 2001-10-26 2002-09-04 中国中医研究院中药研究所 Cinnamon twig decoction extract for preventing and curing hypertension

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133304A (en) * 1997-12-23 2000-10-17 Warner-Lambert Company ACE inhibitor-MMP inhibitor combinations
CN1330556A (en) * 1998-11-06 2002-01-09 G·D·西尔公司 Combination therepy of angiotensin-converting enzyme inhibor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
CN1366986A (en) * 2001-10-26 2002-09-04 中国中医研究院中药研究所 Cinnamon twig decoction extract for preventing and curing hypertension

Also Published As

Publication number Publication date
CN1911428A (en) 2007-02-14

Similar Documents

Publication Publication Date Title
CN100381163C (en) Medicine comprising rilmenidine
CN103341092B (en) Preparation method of powder for treating atrophic vaginitis
CN101007157A (en) Traditional Chinese medicine compound preparation for treating chronic cholecystitis
CN101732688B (en) Amlodipine-containing medicament
CN101773657B (en) Medicine containing sodium nitroprusside
CN103285284B (en) Medical composition for treating senile vaginitis
CN100367956C (en) Medicine for treating hypertension
CN100367959C (en) Medicine contg. irbesartan
CN101732689B (en) Minoxidil-containing medicament
CN101708326B (en) Medicine containing nifedipine
CN101708325B (en) Medicine containing propranolol
CN105250954B (en) A kind of Chinese medicine for treating IBS and preparation method thereof
CN104306662A (en) Traditional Chinese medicine composition for treating neurasthenia and preparation method thereof
CN101810840B (en) Medicament containing terazosin
CN101732687B (en) Methyldopa-containing medicament
CN101732686B (en) Metoprolol-containing medicament
CN101810839B (en) Diltiazem-containing medicine
CN101502635B (en) Medicament composition containing Reserpine
CN101439178B (en) Medicament containing Urapidil
CN101773658B (en) Medicine containing indapamide
CN103330867B (en) Preparation method of powder for treating senile vaginitis
CN102552711B (en) Traditional Chinese medicine composition for treating hypertension
CN101879227B (en) Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof
CN107158268A (en) It is a kind of to treat Chinese medicine composition of hypertension and its preparation method and application
CN101773545A (en) Leucocyte increasing medicament containing batyl alcohol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Yang Xue

Document name: Notice of conformity

Addressee: Yang Xue

Document name: Deemed not to advise

C14 Grant of patent or utility model
GR01 Patent grant
C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Yang Xue

Document name: Notification to Pay the Fees

C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Yang Xue

Document name: Notification of Termination of Patent Right

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee